Last reviewed · How we verify
Advair HFA
Advair HFA combines an inhaled corticosteroid (fluticasone) and a long-acting beta-2 agonist (salmeterol) to reduce airway inflammation and improve bronchodilation in asthma and COPD.
Advair HFA combines an inhaled corticosteroid (fluticasone) and a long-acting beta-2 agonist (salmeterol) to reduce airway inflammation and improve bronchodilation in asthma and COPD. Used for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | Advair HFA |
|---|---|
| Also known as | salmeterol and fluticasone in hydrofluoroalkane (HFA) propellant |
| Sponsor | University of Colorado, Denver |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination |
| Target | Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Fluticasone propionate suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, reducing mucus production and airway edema. Salmeterol is a long-acting beta-2 agonist that binds to beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and improving airflow. Together, they provide both anti-inflammatory and bronchodilatory effects for sustained symptom control.
Approved indications
- Asthma maintenance treatment
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Nervousness/anxiety
- Palpitations
- Oral candidiasis
- Throat irritation
Key clinical trials
- Advair HFA in Healthy and HAPE Predisposed Subjects (PHASE1, PHASE2)
- Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1) (PHASE3)
- Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID (PHASE4)
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- Mechanism(s) of Airflow Limitation During Exacerbation of Asthma (PHASE4)
- Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers (PHASE1)
- Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers (PHASE1)
- Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Advair HFA CI brief — competitive landscape report
- Advair HFA updates RSS · CI watch RSS
- University of Colorado, Denver portfolio CI